BioNTech co-founders Özlem Türeci (L) and Uğur Şahin (Horst Galuschka/picture-alliance/dpa/AP Images)
In wake of IP claims targeting its megablockbuster, BioNTech mulls a few next steps of its own
BioNTech may have more on its mind than just defending itself against CureVac’s claims that their megablockbuster mRNA Covid-19 vaccine Comirnaty violated their in-house IP …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
